My name is Professor Xavier Leleu. I'm head of department of hematology specialized in myeloma, but myeloma in a search you put you in France. And so at ASCO and IHA 2024, I have presented I have made two talks, many of you patients have an early relapse after line one. And the question is how to give you a good treatment in line two, a good treatment that will not oblige a patient to constantly come to the hospital forever until sadly you become you become progressive on myeloma. So in line two, in the CAR-MMAT-2, to be cohort, we have selected patients that were transplanted in G-Ball upfront that relapsed within 18 months from diagnosis. And in second line, we gave these patients the CAR-T named IDCELL, Abecma, which is a CAR-T that you know targets BCMA. 31 patients were recruited in that phase two single arm study and 70% of them were in complete response. And extremely interestingly, these 70% that were in complete response, actually only 3.2% had had a complete response upfront, but 70% got a complete response with the car. The vast majority of the complete response were MAD negative. And now with more than two years follow up, there is the median PFS has not been reached yet. Similarly, the median of our survival has not been reached yet. And the safety profile was actually impressively good. So it tells this second study as a summary, tells us a lot of gives us a lot of information. Number one, it is not difficult to offer a car to patients that are elderly. Number two, you can very nicely rescue patients who in a certain extent failed line one with a line two. Number three, you can rescue patients with a car. Number four, the quality of life of the patients was, as you know, with a car, absolutely amazing. So I hope you will benefit from this treatment. And I think it's a great treatment for line two in patients, transplant ineligible and more elderly.
HealthTree • July 2, 2024